Clinical Trials Browser

Phase 2 × Myelodysplastic Syndromes × devimistat × Clear all

NCT01520805 2016-12-29

Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome

Phase 2 Withdrawn

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute